Download PDF
Horm Metab Res 2011; 43(6): 417-421
DOI: 10.1055/s-0031-1275719
Humans, Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Subclinical Hypothyroidism and the Prevalence of the Metabolic Syndrome

C. Liu1 , W. A. Scherbaum2 , M. Schott2 , S. Schinner2
  • 1Department of Endocrinology, First Affiliated Hospital, Nanjing Medical University, Nanjing, P. R. China
  • 2Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany
Further Information

Publication History

received 14.06.2010

accepted 24.03.2011

Publication Date:
21 April 2011 (online)

Also available at
    Permissions and Reprints

Abstract

There is currently controversial data regarding the prevalence of MS among SCH patients. The aim of the study was to investigate the prevalence of MS in an adult population with SCH. A cross-sectional study was conducted among 6 998 adults in China. Epidemiological information and medical data were obtained (fasting plasma glucose, triglycerides, high density lipoprotein-C, and thyroid function). The IDF criteria were applied for the diagnosis of MS. SCH was defined as TSH more than 4.5 mIU/l with normal values for FT3 and FT4. Among the 6 560 participants, 21.5% were diagnosed with MS and 8.2% suffered from SCH. MS was found in 21.3% in the euthyroidism (EUT) group and in 25.7% in the SCH group (p<0.05). However, this difference between EUT and SCH in MS prevalence was not statistically significant after adjusting for age. Of note, the prevalence of MS increased with age. The proportions of systemic hypertension, hypertriglyceridemia, impaired fasting glucose, and low HDL-C were 86.7, 59.7, 45.1 and 65.9% in EUT while the corresponding values in SCH were 89.9, 63.8, 39.9 and 72.5%, respectively (the differences, however, did not reach statistical significance). The prevalence of high BP, high TG, elevated FBP, and low HDL-C as well as the percentage of patients fulfilling the IDF criteria for the metabolic syndrome are not significantly different among SCH and EUT after adjusting for age. Therefore, subclinical hypothyroidism appears not as an independent risk factor for the metabolic syndrome in this population.

Key words

thyroid - subclinical hypothyroidism - metabolic syndrome - TSH

References

  • 1 Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome.  Lancet. 2010;  375 181-183
    Google Scholar
  • 2 Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms.  Am Heart J. 2005;  149 33-45
    Google Scholar
  • 3 Garber AJ. The metabolic syndrome.  Med Clin North Am. 2004;  88 837-846, ix
    Google Scholar
  • 4 Lewis JG, Borowski KK, Shand BI, George PM, Scott RS. Plasma sex hormone-binding globulin, corticosteroid-binding globulin, cortisol, and free cortisol levels in outpatients attending a lipid disorders clinic: a cross-sectional study of 1 137 subjects.  Horm Metab Res. 2010;  42 274-279
    Google Scholar
  • 5 Wilson GR, Curry Jr RW. Subclinical thyroid disease.  Am Fam Physician. 2005;  72 1517-1524
    Google Scholar
  • 6 Kvetny J, Wilms L, Pedersen PL, Larsen J. Subclinical hypothyroidism affects mitochondrial function.  Horm Metab Res. 2010;  42 324-327
    Google Scholar
  • 7 Monzani F, Dardano A, Caraccio N. Does treating subclinical hypothyroidism improve markers of cardiovascular risk?.  Treat Endocrinol. 2006;  5 65-81
    Google Scholar
  • 8 Walsh JP, Bremner AP, Bulsara MK, O’leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease.  Arch Intern Med. 2005;  165 2467-2472
    Google Scholar
  • 9 Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects.  J Clin Endocrinol Metab. 2007;  92 491-496
    Google Scholar
  • 10 Teixeira PF, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Melo BA, Buescu A, Costa AJ, Vaisman M. Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial.  Horm Metab Res. 2008;  40 50-55
    Google Scholar
  • 11 Walsh JP, Bremner AP, Bulsara MK, O’leary P, Leedman PJ, Feddema P, Michelangeli V. Thyroid dysfunction and serum lipids: a community-based study.  Clin Endocrinol (Oxf). 2005;  63 670-675
    Google Scholar
  • 12 Uzunlulu M, Yorulmaz E, Oguz A. Prevalence of subclinical hypothyroidism in patients with metabolic syndrome.  Endocr J. 2007;  54 71-76
    Google Scholar
  • 13 Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.  Thyroid. 2003;  13 3-126
    Google Scholar
  • 14 Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.  JAMA. 2002;  287 356-359
    Google Scholar
  • 15 Zhao Z, Nie H, He H, Yan Z, Liu D, Luo Z, Ma L, Ni Y, Chen J, Jing J, Cao T, Yang H, Tepel M, Zhang W, Zhu Z. High-sensitivity C-reactive protein predicts target organ damage in Chinese patients with metabolic syndrome.  Metabolism. 2007;  56 1612-1619
    Google Scholar
  • 16 Hu XS, Guo ZR, Zhou H, Shi ZM, Wu M, Zhang J, Sun GX, Zhou ZY, Pan XQ, Yao CL. Study on the prevalence of metabolic syndrome among 35–74 year-olds in Jiangsu province.  Zhonghua Liu Xing Bing Xue Za Zhi. 2006;  27 751-756
    Google Scholar
  • 17 Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).  J Clin Endocrinol Metab. 2002;  87 489-499
    Google Scholar
  • 18 Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years.  Clin Endocrinol (Oxf). 2004;  61 232-238
    Google Scholar
  • 19 Brabant G, Beck-Peccoz P, Jarzab B, Laurberg P, Orgiazzi J, Szabolcs I, Weetman AP, Wiersinga WM. Is there a need to redefine the upper normal limit of TSH?.  Eur J Endocrinol. 2006;  154 633-637
    Google Scholar
  • 20 Waise A, Price HC. The upper limit of the reference range for thyroid-stimulating hormone should not be confused with a cut-off to define subclinical hypothyroidism.  Ann Clin Biochem. 2009;  46 93-98
    Google Scholar
  • 21 Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling.  J Clin Endocrinol Metab. 2005;  90 5483-5488
    Google Scholar
  • 22 Ruhla S, Weickert MO, Arafat AM, Osterhoff M, Isken F, Spranger J, Schofl C, Pfeiffer AF, Mohlig M. A high normal TSH is associated with the metabolic syndrome.  Clin Endocrinol (Oxf). 2010;  72 696-701
    Google Scholar
  • 23 Garduno-Garcia JJ, virde-Garcia U, Lopez-Carrasco G, Padilla Mendoza ME, Mehta R, Rellano-Campos O, Choza R, Sauque L, Garay-Sevilla ME, Malacara JM, Gomez-Perez FJ, Guilar-Salinas CA. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects.  Eur J Endocrinol. 2010;  163 273-278
    Google Scholar
  • 24 Liu D, Jiang F, Shan Z, Wang B, Wang J, Lai Y, Chen Y, Li M, Liu H, Li C, Xue H, Li N, Yu J, Shi L, Bai X, Hou X, Zhu L, Lu L, Wang S, Xing Q, Teng W. A cross-sectional survey of relationship between serum TSH level and blood pressure.  J Hum Hypertens. 2010;  24 134-138
    Google Scholar

Correspondence

S. SchinnerMD 

Department of Endocrinology,

Diabetes and Rheumatology

University Hospital Düsseldorf

Moorenstr. 5

40225 Düsseldorf

Germany

Phone: +49/211/8117 810

Fax: +49/211/8117 860

Email: sven.schinner@uni-duesseldorf.de

      >